Hemab Therapeutics Holdings, Inc. (COAG)

COAG Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Total Valuation

Fiscal Year	Current	FY 2025	FY 2024
Period Ending	Aug 28, 2026	Dec 31, 2025	Dec 31, 2024
Market Capitalization	2,095	-	-
Market Cap Growth	-	-	-
Enterprise Value	1,638	-	-

Financial Efficiency

Fiscal Year	Current	FY 2025	FY 2024
Period Ending	Aug 28, 2026	Dec 31, 2025	Dec 31, 2024
Debt / Equity Ratio	0.00	0.01	0.02
Net Debt / Equity Ratio	-1.00	-1.00	-0.98
Net Debt / EBITDA Ratio	5.25	2.64	1.72
Net Debt / FCF Ratio	5.89	3.00	1.88
Quick Ratio	35.48	17.62	13.45
Current Ratio	35.85	18.03	13.95
Return on Equity (ROE)	-	-46.99%	-
Return on Assets (ROA)	-	-30.11%	-
Return on Capital Employed (ROCE)	-19.20%	-38.10%	-56.20%

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: May 21, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 28, 2026

Data Sources Report a data error